These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

318 related articles for article (PubMed ID: 18803927)

  • 1. [Surface enhanced laser desorption/ionization (SELDI): proteomics technology and its application in oncology].
    Espejel F; Roa JC
    Med Clin (Barc); 2008 Sep; 131(8):312-7. PubMed ID: 18803927
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Application of serum SELDI proteomic patterns in diagnosis of lung cancer.
    Yang SY; Xiao XY; Zhang WG; Zhang LJ; Zhang W; Zhou B; Chen G; He DC
    BMC Cancer; 2005 Jul; 5():83. PubMed ID: 16029516
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A data-analytic strategy for protein biomarker discovery: profiling of high-dimensional proteomic data for cancer detection.
    Yasui Y; Pepe M; Thompson ML; Adam BL; Wright GL; Qu Y; Potter JD; Winget M; Thornquist M; Feng Z
    Biostatistics; 2003 Jul; 4(3):449-63. PubMed ID: 12925511
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The cancer cell secretome: a good source for discovering biomarkers?
    Pavlou MP; Diamandis EP
    J Proteomics; 2010 Sep; 73(10):1896-906. PubMed ID: 20394844
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Proteic profiling SELDI-TOF and breast cancer: clinical potential applications].
    Gonçalves A; Bertucci F; Birnbaum D; Borg JP
    Med Sci (Paris); 2007 Mar; 23 Spec No 1():23-6. PubMed ID: 17669349
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Proteome analysis for the identification of tumor-associated biomarkers in gastrointestinal cancer.
    Fels LM; Buschmann T; Meuer J; Reymond MA; Lamer S; Röcken C; Ebert MP
    Dig Dis; 2003; 21(4):292-8. PubMed ID: 14752218
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Detection and clinical significance of serum proteomic patterns of breast cancers by surface enhanced laser desorption/ionization time of flight mass spectrometry].
    Zhang GQ; Du J; Pang D
    Zhonghua Zhong Liu Za Zhi; 2006 Mar; 28(3):204-7. PubMed ID: 16875606
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Identification of lung cancer patients by serum protein profiling using surface-enhanced laser desorption/ionization time-of-flight mass spectrometry.
    Han KQ; Huang G; Gao CF; Wang XL; Ma B; Sun LQ; Wei ZJ
    Am J Clin Oncol; 2008 Apr; 31(2):133-9. PubMed ID: 18391596
    [TBL] [Abstract][Full Text] [Related]  

  • 9. SELDI-TOF-MS proteomics of breast cancer.
    Clarke CH; Buckley JA; Fung ET
    Clin Chem Lab Med; 2005; 43(12):1314-20. PubMed ID: 16309366
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical proteomics: searching for better tumour markers with SELDI-TOF mass spectrometry.
    Engwegen JY; Gast MC; Schellens JH; Beijnen JH
    Trends Pharmacol Sci; 2006 May; 27(5):251-9. PubMed ID: 16600386
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Proteomic patterns: their potential for disease diagnosis.
    Xiao Z; Prieto D; Conrads TP; Veenstra TD; Issaq HJ
    Mol Cell Endocrinol; 2005 Jan; 230(1-2):95-106. PubMed ID: 15664456
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Advances in clinical cancer proteomics: SELDI-ToF-mass spectrometry and biomarker discovery.
    Seibert V; Ebert MP; Buschmann T
    Brief Funct Genomic Proteomic; 2005 May; 4(1):16-26. PubMed ID: 15975261
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Proteomic analysis of prostate cancer using surface enhanced laser desorption/ionization mass spectrometry].
    Pan YZ; Xiao XY; Zhao D; Zhang L; Ji GY; Li Y; He DC; Zhao XJ; Yang BX
    Zhonghua Yi Xue Za Zhi; 2005 Nov; 85(45):3172-5. PubMed ID: 16405834
    [TBL] [Abstract][Full Text] [Related]  

  • 14. SELDI-TOF proteomic analysis and cancer detection.
    Henderson NA; Steele RJ
    Surgeon; 2005 Dec; 3(6):383-90, 422. PubMed ID: 16353858
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Proteomic profiling: the potential of Seldi-Tof for the identification of new cancer biomarkers].
    Solassol J; Marin P; Maudelonde T; Mangé A
    Bull Cancer; 2005 Sep; 92(9):763-8. PubMed ID: 16203265
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Classification of cancer types by measuring variants of host response proteins using SELDI serum assays.
    Fung ET; Yip TT; Lomas L; Wang Z; Yip C; Meng XY; Lin S; Zhang F; Zhang Z; Chan DW; Weinberger SR
    Int J Cancer; 2005 Jul; 115(5):783-9. PubMed ID: 15704152
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Contributions of advanced proteomics technologies to cancer diagnosis.
    Ciordia S; de Los Ríos V; Albar JP
    Clin Transl Oncol; 2006 Aug; 8(8):566-80. PubMed ID: 16952845
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Protein profiling for cancer biomarker discovery using matrix-assisted laser desorption/ionization time-of-flight mass spectrometry and infrared imaging: a review.
    Bakry R; Rainer M; Huck CW; Bonn GK
    Anal Chim Acta; 2011 Mar; 690(1):26-34. PubMed ID: 21414433
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Surface-enhanced laser desorption ionization time-of-flight mass spectrometry (SELDI TOF-MS) and ProteinChip technology in proteomics research.
    Seibert V; Wiesner A; Buschmann T; Meuer J
    Pathol Res Pract; 2004; 200(2):83-94. PubMed ID: 15237917
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Application of mass spectrometry to the discovery of biomarkers for detection of prostate cancer.
    Semmes OJ; Malik G; Ward M
    J Cell Biochem; 2006 Jun; 98(3):496-503. PubMed ID: 16552720
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.